While the latest rate cut is clearly positive and is long overdue, the PBoC is still behind the curve. Monetary conditions remain far too tight, and further easing is likely.
Speaking at China’s annual parliamentary hearing, Premier Li Kequiang noted that, “The downward pressure on China’s economy is intensifying,” and that 2015 would be a tough year for growth. Indeed, the Chinese government downgraded its official target for growth to ‘around’ 7%.
Amidst this sober evaluation, China’s monetary conditions index has continued to deteriorate, driven by both rising real rates and a rising currency. This is disconcerting for asset prices, especially domestic A shares, as the market has rallied strongly since mid last year and is no longer cheap. The rally has partly been driven by expectations of policy easing and an improvement in monetary conditions – which have clearly failed to materialize.
For now our China strategists maintain a neutral rating on domestic A shares, as the risk-return profile of this asset class is roughly balanced. On one hand, there is a strong case that the PBoC should continue to ease, which will eventually lead to improvement in monetary conditions and a bid up in stock prices. On the other hand, the market may disappoint if investors decide that policy easing so far has not been effective and the PBoC continues to drag its feet. In this environment, any aggressive directional bet would be premature.
Deteriorating monetary conditions also bode poorly for investable Chinese stocks, but the case for this asset class is strengthened by attractive valuation. Chinese investable shares are still trading at hefty discounts to their historical averages – which justifies risk-taking, especially within the broader backdrop of monetary easing. The case for relative outperformance of Chinese investable stocks versus the EM benchmark is more compelling. China is among the few countries that have ample room for monetary easing, and Chinese stocks are still trading at discounts to their EM and global peers despite the past two years’ sharp outperformance. Chinese investable stocks will likely continue to be positively rerated going forward.